Menu
Annual · values2025202420232022
Operating Cash Flow-11.22 M USD-10.18 M USD-7.36 M USD-8.35 M USD
Depreciation & Amortization138069 USD131188 USD129653 USD125885 USD
Stock-Based Compensation62744 USD245053 USD151505 USD184465 USD
Capital Expenditures24213 USD8569 USD26544 USD33101 USD
Cash Flow from Investing-182909 USD-379246 USD-318259 USD-336761 USD
Cash Flow from Financing8.92 M USD13.32 M USD5.98 M USD4.13 M USD
Dividends Paid
Stock Buybacks
Free Cash Flow-11.25 M USD-10.19 M USD-7.39 M USD-8.38 M USD

Azitra Inc. is a clinical-stage biotechnology company that focuses on harnessing the therapeutic potential of the human microbiome. The company is dedicated to developing microbiome-based treatments to address dermatological conditions and improve skin health. Azitra leverages its proprietary platform to design therapies that utilize commensal microbiota, which are the naturally occurring bacteria on human skin, for combating various skin diseases. By targeting skin-associated microbiomes, Azitra aims to create safe and effective treatment options for conditions that may not respond well to conventional treatments. Its innovative approach positions Azitra in the emerging field of microbiome therapy, impacting healthcare and dermatology industries. With its specialized focus, Azitra plays a significant role in advancing biotechnology innovations and contributing to the evolving narrative of precision medicine and personalized healthcare.